Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is evaluating daratumumab- and carfilzomib-based induction, consolidation, and maintenance therapy in transplant-eligible ultra high…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extramedullary Multiple Myeloma
• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Carfilzomib (carfilzomib)
• Daratumumab (daratumumab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Multiple Myeloma, Primary Plasma Cell Leukemia | Phase 2 | Status: RECRUITING